Longevity drugs · senolytic
Dasatinib + Quercetin
The first senolytic combination; striking in mice, very early in humans.
Not medical advice — talk to a licensed clinician. Content is educational, reflects published literature, and is not a recommendation to start, stop or change any treatment.
What it is
Dasatinib is a leukemia drug; quercetin is a plant flavonoid. Together they clear senescent ('zombie') cells in models.
How it works, in plain English
Senescent cells accumulate with age and secrete inflammatory signals. D+Q triggers their self-destruction, reducing that inflammatory burden.
What the human evidence shows
Extended healthspan in aged mice. Small human pilot studies in idiopathic pulmonary fibrosis and diabetic kidney disease showed reduced senescent markers and some function signals. Safety in healthy people is unestablished.
Regrowth grade D: Mostly preclinical.
Typical protocols in the literature
Pilot trials used intermittent 'hit-and-run' dosing over a few days, not continuous use.
Described for education, not as dosing advice.
Side effects & interactions
Side effects
- Dasatinib: low blood counts, fluid retention, GI effects
- Quercetin: generally mild
Interactions
- Many CYP3A4 interactions with dasatinib
- Acid-reducing medications
Key studies
- Xu et al. 2018 — senolytics in aged mice
- Justice et al. 2019 — IPF pilot
- Hickson et al. 2019 — diabetic kidney disease
Citations pending medical review